Acrux Ltd (ASX: ACR) Share Price and News

Mr Dobinson is the founder and former CEO of Acrux and has been a Director since 1998. He was first appointed as Chairman in January 2006, additionally holding the role of Executive Chairman from July 2012 to October 2014. He has a background in investment banking and stockbroking.

Dr Brooke has more than 30 years of venture capital experience and founded GBS Venture Partners in 1996. In 2014 he retired from GBS and now concentrates on privately investing in a small number of companies. He was President of Med vest, a US based early stage venture capital group he founded with Johnson & Johnson. His experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. He is licensed in clinical medicine by the Medical Board of Australia, and his postgraduate work was in anaesthetics and intensive care. He is member of the Risk Committee and Human Capital Committee.

Mr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He led Tijan Ventures, a life sciences advisory business focussed on strategic advisory and leadership services and acquiring cell and gene therapy assets. He was previously CEO and Managing Director of Cell Therapies Pty Ltd and President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles encompassing development and commercialisation of generic pharmaceuticals, devices, biologics and cellular therapies with Mayne Pharma Ltd prior to its acquisition by Hospira. He began his career as an engagement manager with McKinsey & Company. He has been a Non executive Director of BioMelbourne Network Inc, chaired the European Generic Medicines Association Biosimilars and Biotechnology Committee and was a Non executive Director of the Alliance for Regenerative Medicine and Non executive Director of the Generic Medicines Industry Association. He is member of the Risk Committee and Chair of the Human Capital Committee.

Mr Brumley has 30 years of experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. He was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is Chair of the Risk Committee and member of the Human Capital Committee.

Mr Warmbrunn has over 25 years of experience in building and scaling businesses, particularly in the healthcare sector. For 12 years he held senior commercial roles at Ego Pharmaceuticals, Australias leading dermatological pharmaceutical company, leading growth of the companys export business to over 50% of turnover. He started his industry career in sales at Sandoz and held various management roles as it merged to form Novartis, eventually establishing the companys OTC business in Australia and New Zealand. He also held a senior role with Bristol Myers Squibb.

-

-

-

-